THE partnership between Ho Wah Genting Bhd’s wholly-owned subsidiary HWGB Biotech Sdn Bhd and Wuhan Easydiagnosis Biomedicine Co Ltd is bearing fruit following the positive evaluation by the Ministry of Health (MOH) on their COVID-19 test kits.
Wuhan Easydiagnosis has authorised HWGB Biotech as the distributor of its COVID-19 nucleic acid test kits and nucleic acid extraction reagents in Malaysia with a one-year validity period beginning March 20 this year.
On Oct 13, it was announced that the MOH had in a technical report showed that the COVID-19 test kits have passed with 100% accuracy the sensitivity tests administered by the MOH.
Wuhan Easydiagnosis is a leading manufacturer of in-vitro diagnostic devices based in Wuhan, China and specialising in the development, production and distribution of point-of-care testing or bedside testing rapid diagnostic reagents and related equipment to more than 20 countries.
Listed on the Shezhen Stock Exchange, an exchange well-known for listings of high-growth technology start-ups, Wuhan Easydiagnosis has a strong research and development team along with 100,000 production lines in international-grade workshops.
Commenting on the positive development, HWGB Biotech’s general manager (medical & pharmaceutical research) Dr Yaman Walid Kassab said the MOH’s positive evaluation on the COVID-19 test kits along with the authorisation to distribute them is a strong testament to the robustness and reliability of the product.
“We believe that our relationship with Wuhan Easydiagnosis will grow from strength to strength as we work together and explore other avenues of collaboration in Malaysia and Southeast Asia,” he added. – Oct 15, 2020
